AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Agios Pharmaceuticals: FDA Extends PDUFA Goal Date for PYRUKYND in Thalassemia to December 7, 2025
ByAinvest
Thursday, Sep 4, 2025 7:01 am ET1min read
Agios Pharmaceuticals has announced that the FDA has extended the PDUFA goal date for PYRUKYND, an oral pyruvate kinase activator for treating thalassemia, by three months to December 7, 2025. This extension is due to a major amendment to the PYRUKYND sNDA, including a proposed Risk Evaluation and Mitigation Strategy to mitigate the risk of hepatocellular injury. The company remains confident in the drug's favorable benefit-risk profile and looks forward to bringing it to adult patients with thalassemia in the US.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet